IL320332A - שיטות לטיפול בסרטן - Google Patents

שיטות לטיפול בסרטן

Info

Publication number
IL320332A
IL320332A IL320332A IL32033225A IL320332A IL 320332 A IL320332 A IL 320332A IL 320332 A IL320332 A IL 320332A IL 32033225 A IL32033225 A IL 32033225A IL 320332 A IL320332 A IL 320332A
Authority
IL
Israel
Prior art keywords
methods
treating cancer
cancer
treating
Prior art date
Application number
IL320332A
Other languages
English (en)
Original Assignee
Antares Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antares Therapeutics Inc filed Critical Antares Therapeutics Inc
Publication of IL320332A publication Critical patent/IL320332A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL320332A 2022-10-21 2023-10-20 שיטות לטיפול בסרטן IL320332A (he)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263418089P 2022-10-21 2022-10-21
US202363443877P 2023-02-07 2023-02-07
US202363469252P 2023-05-26 2023-05-26
PCT/US2023/077441 WO2024086809A1 (en) 2022-10-21 2023-10-20 Methods for treating cancer

Publications (1)

Publication Number Publication Date
IL320332A true IL320332A (he) 2025-06-01

Family

ID=88874777

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320332A IL320332A (he) 2022-10-21 2023-10-20 שיטות לטיפול בסרטן

Country Status (10)

Country Link
EP (1) EP4605392A1 (he)
JP (1) JP2025538097A (he)
KR (1) KR20250110370A (he)
CN (1) CN120418247A (he)
AU (1) AU2023364551A1 (he)
CL (1) CL2025001163A1 (he)
IL (1) IL320332A (he)
MX (1) MX2025004532A (he)
TW (1) TW202421628A (he)
WO (1) WO2024086809A1 (he)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202303419D0 (en) * 2023-03-08 2023-04-19 Otsuka Pharma Co Ltd Compounds
EP4793277A1 (en) * 2023-10-12 2026-08-19 Nutshell Therapeutics (Shanghai) Co., Ltd. Carboxylic acid compound and preparation method therefor and use thereof
AU2024295989B2 (en) 2023-10-20 2026-08-13 Nutshell Therapeutics (Shanghai) Co., Ltd. N-sulfonamide nitrogen-containing fused heterocyclic compound, and application thereof
TW202604504A (zh) * 2024-05-11 2026-02-01 大陸商上海齊魯製藥研究中心有限公司 含氮並環化合物、含其的藥物組合物及其應用
WO2026011032A1 (en) * 2024-07-03 2026-01-08 Antares Therapeutics, Inc. Methods for treating cancer
WO2026024861A1 (en) * 2024-07-23 2026-01-29 Merck Sharp & Dohme Llc Compounds targeting mutations in p53 and uses thereof
WO2026024896A1 (en) * 2024-07-24 2026-01-29 Merck Sharp & Dohme Llc Compounds targeting mutations in p53 and uses thereof
WO2026161455A1 (en) 2025-01-22 2026-07-30 Antares Therapeutics, Inc. Methods for treating p53-associated cancer
WO2026158642A1 (zh) * 2025-01-24 2026-07-30 首药控股(北京)股份有限公司 一种新型杂环化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10906900B2 (en) * 2016-09-26 2021-02-02 Centre National De La Recherche Scientifique Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases
WO2022213975A1 (en) * 2021-04-08 2022-10-13 Jacobio Pharmaceuticals Co., Ltd. Compounds targeting y220c mutant of p53

Also Published As

Publication number Publication date
TW202421628A (zh) 2024-06-01
WO2024086809A1 (en) 2024-04-25
EP4605392A1 (en) 2025-08-27
AU2023364551A1 (en) 2025-05-08
CL2025001163A1 (es) 2025-10-03
JP2025538097A (ja) 2025-11-26
KR20250110370A (ko) 2025-07-18
CN120418247A (zh) 2025-08-01
MX2025004532A (es) 2025-07-01

Similar Documents

Publication Publication Date Title
IL304275A (he) שיטות לטיפול בסרטן
IL312680A (he) שיטות לטיפול בסרטן
IL287907A (he) שיטות לטיפול בסרטן
PT4225297T (pt) Terapia de combinação para o tratamento de cancro
ZA202310076B (en) Combination therapies for treating cancer
IL319513A (he) תרכובות לטיפול בסרטן
AU2024225706A1 (en) Methods for treating breast cancer
IL289811A (he) שיטה לטיפול בסרטן
IL316017A (he) טיפול משולב לטיפול בסרטן
IL316016A (he) טיפול משולב לטיפול בסרטן
PL4048284T3 (pl) Metoda leczenia nowotworów
AU2024410299A1 (en) Methods for treating cancer
IL305974A (he) שילובים רוקחיים לטיפול בסרטן
IL317573A (he) טיפול משולב לטיפול בסרטן
IL316019A (he) טיפול משולב לטיפול בסרטן
IL320471A (he) שיטות לטיפול בסרטן המבטא dll3
IL317472A (he) ארבציקלין לטיפול בסרטן
GB202412414D0 (en) Methods for treating cancer
IL272390A (he) שיטות לטיפול בסרטן
CA3274939A1 (en) Methods for treating dll3-expressing cancer
CA3219579A1 (en) Methods for treating myc-amplified cancer
CA3271139A1 (en) Methods for treating cancer
HK40129670A (en) Methods for treating cancer
CA3270023A1 (en) Methods for treating cancer
HK40109687A (en) Methods for treating cancer